Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Debt (2020 - 2025)

Historic Total Debt for Zevra Therapeutics (ZVRA) over the last 8 years, with Q3 2025 value amounting to $61.3 million.

  • Zevra Therapeutics' Total Debt rose 408.46% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 408.46%. This contributed to the annual value of $59.5 million for FY2024, which is 3913.86% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Total Debt of $61.3 million as of Q3 2025, which was up 408.46% from $60.7 million recorded in Q2 2025.
  • Zevra Therapeutics' Total Debt's 5-year high stood at $61.3 million during Q3 2025, with a 5-year trough of $781000.0 in Q1 2021.
  • Its 5-year average for Total Debt is $36.2 million, with a median of $38.8 million in 2023.
  • In the last 5 years, Zevra Therapeutics' Total Debt crashed by 71.09% in 2023 and then surged by 35895.04% in 2024.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Total Debt stood at $781000.0 in 2021, then soared by 1538.92% to $12.8 million in 2022, then soared by 234.11% to $42.8 million in 2023, then surged by 39.14% to $59.5 million in 2024, then increased by 3.04% to $61.3 million in 2025.
  • Its Total Debt was $61.3 million in Q3 2025, compared to $60.7 million in Q2 2025 and $60.1 million in Q1 2025.